作者
M Witzenrath, APJ Vlaar, M Bauer, D Annane, L Heunks, B Mourvillier, L Hercilla Vasquez, T Welte, P van Paassen, S de Bruin, EHT Lim, MC Brouwer, PR Tuinman, JF Saraiva, G Marx, SM Lobo, R Boldo, J Simon-Campos, AD Cornet, A Grebenyuk, J Engelbrecht, M Habel, C Thielert, J Dickinson, S Rückinger, R Zerbib, D Neukirchen, K Pilz, R Guo, D van de Beek, NC Riedemann, PANAMO Study Group
发表日期
2023/5
图书
D16. ADVANCING THE SCIENCE OF ARDS AND ACUTE RESPIRATORY FAILURE
页码范围
A6237-A6237
出版商
American Thoracic Society
简介
Rationale
Infection by SARS-CoV-2 leads to a viral pneumonia and, in the worst case, severe acute respiratory distress syndrome (ARDS). In critically ill COVID-19 patients, high levels of the anaphylatoxin C5a are generated leading to myeloid cell infiltration in damaged organs, excessive lung inflammation and endothelialitis. Blocking the C5a-C5aReceptor axis in these patients could improve outcomes. This multinational, adaptive design, Phase 3 randomized, double-blind, placebo (P)-controlled study investigated the effects of Vilobelimab (Vilo), a monoclonal anti-C5a antibody preserving membrane attack complex, on survival in critically ill COVID-19 patients. Methods
From 46 sites on 4 continents, 369 COVID-19 patients (N= 368; one excluded for randomization error) requiring invasive mechanical ventilation were randomized within 48 hours after intubation to receive 6 infusions of 800 mg of Vilo (n= 177) or …学术搜索中的文章
M Witzenrath, APJ Vlaar, M Bauer, D Annane… - D16. ADVANCING THE SCIENCE OF ARDS AND …, 2023